Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab combinations versus pembrolizumab in first-line PD-L1 high advanced non-small cell lung cancer
MOH_2018-12-18_004846Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cemiplimab, ipilimumab and pembrolizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Progression-free survival. Started Aug 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2018-12-18_004846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-12-18_004846.